222 related articles for article (PubMed ID: 21830928)
21. Fusion of nonclinical and clinical data to predict human drug safety.
Johnson DE
Expert Rev Clin Pharmacol; 2013 Mar; 6(2):185-95. PubMed ID: 23473595
[TBL] [Abstract][Full Text] [Related]
22. Statistical and graphical approaches for disproportionality analysis of spontaneously-reported adverse events in pharmacovigilance.
Zink RC; Huang Q; Zhang LY; Bao WJ
Chin J Nat Med; 2013 May; 11(3):314-20. PubMed ID: 23725848
[TBL] [Abstract][Full Text] [Related]
23. The validity of sequence symmetry analysis (SSA) for adverse drug reaction signal detection.
Wahab IA; Pratt NL; Wiese MD; Kalisch LM; Roughead EE
Pharmacoepidemiol Drug Saf; 2013 May; 22(5):496-502. PubMed ID: 23412832
[TBL] [Abstract][Full Text] [Related]
24. A conditional maximized sequential probability ratio test for pharmacovigilance.
Li L; Kulldorff M
Stat Med; 2010 Jan; 29(2):284-95. PubMed ID: 19941282
[TBL] [Abstract][Full Text] [Related]
25. Bayesian statistics in medical devices: innovation sparked by the FDA.
Campbell G
J Biopharm Stat; 2011 Sep; 21(5):871-87. PubMed ID: 21830920
[TBL] [Abstract][Full Text] [Related]
26. Methods for drug safety signal detection in longitudinal observational databases: LGPS and LEOPARD.
Schuemie MJ
Pharmacoepidemiol Drug Saf; 2011 Mar; 20(3):292-9. PubMed ID: 20945505
[TBL] [Abstract][Full Text] [Related]
27. Drug safety special: chasing shadows.
Frantz S
Nature; 2005 Mar; 434(7033):557-8. PubMed ID: 15800592
[No Abstract] [Full Text] [Related]
28. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
Wysowski DK; Swartz L
Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
[TBL] [Abstract][Full Text] [Related]
29. Bayesian decision procedures based on logistic regression models for dose-finding studies.
Whitehead J; Williamson D
J Biopharm Stat; 1998 Jul; 8(3):445-67. PubMed ID: 9741859
[TBL] [Abstract][Full Text] [Related]
30. Detecting potential safety issues in large clinical or observational trials by Bayesian screening when event counts arise from poisson distributions.
Gould AL
J Biopharm Stat; 2013; 23(4):829-47. PubMed ID: 23786257
[TBL] [Abstract][Full Text] [Related]
31. FDA attempting to overcome major roadblocks in monitoring drug safety.
Zielinski SL
J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
[No Abstract] [Full Text] [Related]
32. Drug therapy: safety, effectiveness, and economics.
Brandys J
Przegl Lek; 2001; 58(4):226-8. PubMed ID: 11450340
[TBL] [Abstract][Full Text] [Related]
33. Empirical Bayes models of Poisson clinical trials and sample size determination.
Zaslavsky BG
Pharm Stat; 2010; 9(2):133-41. PubMed ID: 19513984
[TBL] [Abstract][Full Text] [Related]
34. False discovery rate estimation for frequentist pharmacovigilance signal detection methods.
Ahmed I; Dalmasso C; Haramburu F; Thiessard F; Broët P; Tubert-Bitter P
Biometrics; 2010 Mar; 66(1):301-9. PubMed ID: 19432790
[TBL] [Abstract][Full Text] [Related]
35. Pharmacovigilance data mining with methods based on false discovery rates: a comparative simulation study.
Ahmed I; Thiessard F; Miremont-Salamé G; Bégaud B; Tubert-Bitter P
Clin Pharmacol Ther; 2010 Oct; 88(4):492-8. PubMed ID: 20811349
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.
Bennett CL; Nebeker JR; Yarnold PR; Tigue CC; Dorr DA; McKoy JM; Edwards BJ; Hurdle JF; West DP; Lau DT; Angelotta C; Weitzman SA; Belknap SM; Djulbegovic B; Tallman MS; Kuzel TM; Benson AB; Evens A; Trifilio SM; Courtney DM; Raisch DW
Arch Intern Med; 2007 May; 167(10):1041-9. PubMed ID: 17533207
[TBL] [Abstract][Full Text] [Related]
37. [Organization and results of drug vigilance in France].
Bégaud B; Chaslerie A; Haramburu F
Rev Epidemiol Sante Publique; 1994; 42(5):416-23. PubMed ID: 7973001
[TBL] [Abstract][Full Text] [Related]
38. Reports of hyperkalemia after publication of RALES--a pharmacovigilance study.
Hauben M; Reich L; Gerrits CM
Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):775-83. PubMed ID: 16804951
[TBL] [Abstract][Full Text] [Related]
39. Comparing data mining methods on the VAERS database.
Banks D; Woo EJ; Burwen DR; Perucci P; Braun MM; Ball R
Pharmacoepidemiol Drug Saf; 2005 Sep; 14(9):601-9. PubMed ID: 15954077
[TBL] [Abstract][Full Text] [Related]
40. Bayesian versus frequentist hypotheses testing in clinical trials with dichotomous and countable outcomes.
Zaslavsky BG
J Biopharm Stat; 2010 Sep; 20(5):985-97. PubMed ID: 20721786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
